US Patent Issued to MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, MILLENNIUM PHARMACEUTICALS on June 17 for "Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof" (New York, Massachusetts Inventors)

ALEXANDRIA, Va., June 19 -- United States Patent no. 12,331,129, issued on June 17, was assigned to MEMORIAL SLOAN-KETTERING CANCER CENTER (New York), SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (New York), MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (New York) and MILLENNIUM PHARMACEUTICALS INC. (Cambridge, Mass.).

"Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof" was invented by Michel Sadelain (New York), Sascha P. Haubner (New York), Jorge Mansilla-Soto (Forest Hills, N.Y.), Xingyue He (Cambridge, Mass.) and Gary Shapiro (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and ...